3idi: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:3idi.png|left|200px]] | |||
[[Image:3idi. | |||
{{STRUCTURE_3idi| PDB=3idi | SCENE= }} | {{STRUCTURE_3idi| PDB=3idi | SCENE= }} | ||
===Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide ALDKWNQ=== | ===Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide ALDKWNQ=== | ||
{{ABSTRACT_PUBMED_19740978}} | {{ABSTRACT_PUBMED_19740978}} | ||
==About this Structure== | ==About this Structure== | ||
[[3idi]] is a 3 chain structure of [[Monoclonal Antibody]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3IDI OCA]. | |||
==See Also== | |||
*[[Monoclonal Antibody|Monoclonal Antibody]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:019740978</ref><references group="xtra"/> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Bryson, S.]] | [[Category: Bryson, S.]] | ||
Line 33: | Line 24: | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
[[Category: Mper]] | [[Category: Mper]] | ||
Revision as of 07:16, 27 July 2012
Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide ALDKWNQCrystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide ALDKWNQ
Template:ABSTRACT PUBMED 19740978
About this StructureAbout this Structure
3idi is a 3 chain structure of Monoclonal Antibody with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See AlsoSee Also
ReferenceReference
- ↑ Bryson S, Julien JP, Hynes RC, Pai EF. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol. 2009 Nov;83(22):11862-75. Epub 2009 Sep 9. PMID:19740978 doi:10.1128/JVI.01604-09